157 related articles for article (PubMed ID: 31156883)
1. A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia.
D'Mello S; Shum L
Eur J Hosp Pharm; 2016 Nov; 23(6):359-363. PubMed ID: 31156883
[TBL] [Abstract][Full Text] [Related]
2. Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy.
Wahbi K; Bassez G; Duchateau J; Salort-Campana E; Vicart S; Desaphy JF; Labombarda F; Sellal JM; Deharo JC
Arch Cardiovasc Dis; 2024; 117(6-7):450-456. PubMed ID: 38677940
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment for myotonia.
Trip J; Drost G; van Engelen BG; Faber CG
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD004762. PubMed ID: 16437496
[TBL] [Abstract][Full Text] [Related]
4. Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2.
Mousele C; Matthews E; Pitceathly RDS; Hanna MG; MacDonald S; Savvatis K; Carr A; Turner C
Neurol Clin Pract; 2021 Oct; 11(5):e682-e685. PubMed ID: 34840883
[TBL] [Abstract][Full Text] [Related]
5. Expert Insights from a Delphi-driven Neurologists' Panel: Real-world Mexiletine use in Patients with Myotonic Disorders in Italy.
Lidonnici D; Brambilla P; Ravasio R; Zozulya-Weidenfeller A; Beiderbeck A; van Aswegen M; Oliveira R; Sansone VA
J Neuromuscul Dis; 2024; 11(2):411-423. PubMed ID: 38306059
[TBL] [Abstract][Full Text] [Related]
6. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
Logigian EL; Martens WB; Moxley RT; McDermott MP; Dilek N; Wiegner AW; Pearson AT; Barbieri CA; Annis CL; Thornton CA; Moxley RT
Neurology; 2010 May; 74(18):1441-8. PubMed ID: 20439846
[TBL] [Abstract][Full Text] [Related]
7. Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.
Heatwole C; Luebbe E; Rosero S; Eichinger K; Martens W; Hilbert J; Dekdebrun J; Dilek N; Zizzi C; Johnson N; Puwanant A; Tawil R; Schifitto G; Beck CA; Richeson JF; Zareba W; Thornton C; McDermott MP; Moxley R
Neurology; 2021 Jan; 96(2):e228-e240. PubMed ID: 33046619
[TBL] [Abstract][Full Text] [Related]
8. Impact of restricted access to, and low awareness of, mexiletine on people with myotonia: a real-world European survey.
Díaz-Manera J; Urtizberea JA; Schey C; Kole A; von Gallwitz P; Whiting A; Foerster D; Zozulya-Weidenfeller A
Neuromuscul Disord; 2023 Feb; 33(2):208-217. PubMed ID: 36706619
[TBL] [Abstract][Full Text] [Related]
9. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.
Andersen G; Hedermann G; Witting N; Duno M; Andersen H; Vissing J
Brain; 2017 Sep; 140(9):2295-2305. PubMed ID: 29050397
[TBL] [Abstract][Full Text] [Related]
10. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes.
Trivedi JR; Bundy B; Statland J; Salajegheh M; Rayan DR; Venance SL; Wang Y; Fialho D; Matthews E; Cleland J; Gorham N; Herbelin L; Cannon S; Amato A; Griggs RC; Hanna MG; Barohn RJ;
Brain; 2013 Jul; 136(Pt 7):2189-200. PubMed ID: 23771340
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.
Vicart S; Franques J; Bouhour F; Magot A; Péréon Y; Sacconi S; Nadaj-Pakleza A; Behin A; Zahr N; Hézode M; Fournier E; Payan C; Lacomblez L; Fontaine B
Neuromuscul Disord; 2021 Nov; 31(11):1124-1135. PubMed ID: 34702654
[TBL] [Abstract][Full Text] [Related]
12. Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.
Stunnenberg BC; Raaphorst J; Groenewoud HM; Statland JM; Griggs RC; Woertman W; Stegeman DF; Timmermans J; Trivedi J; Matthews E; Saris CGJ; Schouwenberg BJ; Drost G; van Engelen BGM; van der Wilt GJ
JAMA; 2018 Dec; 320(22):2344-2353. PubMed ID: 30535218
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of mexiletine effect on conduction delay and bradyarrhythmic complications in patients with myotonic dystrophy type 1 over long-term follow-up.
Vio R; Zorzi A; Bello L; Bozzoni V; Botta A; Rivezzi F; Leoni L; Migliore F; Bertaglia E; Iliceto S; Pegoraro E; Corrado D; Calore C
Heart Rhythm; 2020 Nov; 17(11):1944-1950. PubMed ID: 32525073
[TBL] [Abstract][Full Text] [Related]
14. Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel.
Chapman AM; Schurer M; Weijers L; Omar A; Lee H; Weidenfeller AZ; Ellis C; Sonecha S; Schneider-Gold C
BMC Neurol; 2021 Dec; 21(1):467. PubMed ID: 34852780
[TBL] [Abstract][Full Text] [Related]
15. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.
Stunnenberg BC; Woertman W; Raaphorst J; Statland JM; Griggs RC; Timmermans J; Saris CG; Schouwenberg BJ; Groenewoud HM; Stegeman DF; van Engelen BG; Drost G; van der Wilt GJ
BMC Neurol; 2015 Mar; 15():43. PubMed ID: 25880166
[TBL] [Abstract][Full Text] [Related]
16. Treatment of myotonia with antiarrhythmic drugs.
Kwieciński H; Ryniewicz B; Ostrzycki A
Acta Neurol Scand; 1992 Oct; 86(4):371-5. PubMed ID: 1455983
[TBL] [Abstract][Full Text] [Related]
17. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.
Statland JM; Bundy BN; Wang Y; Rayan DR; Trivedi JR; Sansone VA; Salajegheh MK; Venance SL; Ciafaloni E; Matthews E; Meola G; Herbelin L; Griggs RC; Barohn RJ; Hanna MG;
JAMA; 2012 Oct; 308(13):1357-65. PubMed ID: 23032552
[TBL] [Abstract][Full Text] [Related]
18. [Dystrophic and non-dystrophic myotonias].
Montagnese F; Schoser B
Fortschr Neurol Psychiatr; 2018 Sep; 86(9):575-583. PubMed ID: 30248690
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Desaphy JF; Carbonara R; Costanza T; Conte Camerino D
Exp Neurol; 2014 May; 255(100):96-102. PubMed ID: 24613829
[TBL] [Abstract][Full Text] [Related]
20. Repurposing of sodium channel antagonists as potential new anti-myotonic drugs.
Matthews E; Hanna MG
Exp Neurol; 2014 Nov; 261():812-5. PubMed ID: 25218042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
